Literature DB >> 11456261

Clinical differences between benign and malignant pheochromocytomas.

B Glodny1, G Winde, R Herwig, A Meier, C Kühle, S Cromme, H Vetter.   

Abstract

Most pheochromocytomas can be cured by resection. In view of the unfavourable prognosis for surgical therapy in cases of late tumour detection and malignant tumours, the aim of the present study is to differentiate between typical signs and symptoms of malignant versus benign pheochromocytomas. We investigated the records of 133 patients retrospectively (1967-1998). In cases of benign tumours (104 of 133, mean age 42+/-15.8 years) tumour size was 5.9+/-3.4 cm, and history was 47.4+/-75.4 months. 7.7% of the tumours were extraadrenal, and 77% had paroxysmal manifestations. The other 29 patients (mean age: 39.2+/-21.9 years) had malignant lesions (tumour size: 9.4+/-5.9 cm (p=0.0022); history: 7.4+/-5.6 months (p=0.0137); extraadrenal: 24.1% (p=0.0219); paroxysmal: 37.9% (p=0.0012)). Symptoms of patients with benign tumours were hypertension (80%), headaches (42.3%), sweating (30.8%), tachycardia (26%) and pallor (24%) (Malignant: Hypertension 46%, p=0.0873; headaches 11%, p=0.0008; sweating 11%, p=0.0196; tachycardia 14%, p=0.1961 and pallor 0%, p=0.0010). Abdominal pain and dorsalgia occurred more frequently in malignant pheochromocytomas (26% versus 7%, p=0.0014). Unusually short histories and extraadrenal localization appear to be suspicious for malignancy. The "typical" clinical signs and symptoms occur more frequently in patients with benign tumours and can therefore be regarded as typical signs of benign pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456261     DOI: 10.1507/endocrj.48.151

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  15 in total

1.  Malignant pheochromocytoma: new malignancy criteria.

Authors:  Pierre de Wailly; Luigi Oragano; Francois Radé; Anthony Beaulieu; Vincent Arnault; Pierre Levillain; Jean Louis Kraimps
Journal:  Langenbecks Arch Surg       Date:  2011-11-09       Impact factor: 3.445

2.  Flank pain after minor trauma as the initial manifestation of malignant pheochromocytoma; a case report.

Authors:  Hassan Niroomand; Atoosa Bagheri-Behzad; Eghlim Nemati; Mehrdad Taghipour; Mohsen Motalebi
Journal:  J Nephropharmacol       Date:  2015-06-26

3.  Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.

Authors:  Irfan Jawed; Margarita Velarde; Roland Därr; Katherine I Wolf; Karen Adams; Aradhana M Venkatesan; Sanjeeve Balasubramaniam; Marianne S Poruchynsky; James C Reynolds; Karel Pacak; Tito Fojo
Journal:  Cell Mol Neurobiol       Date:  2018-04-05       Impact factor: 5.046

4.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 5.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

6.  Metastatic pheochromocytoma: does the size and age matter?

Authors:  Tomáš Zelinka; Zdeněk Musil; Jaroslava Dušková; Deborah Burton; Maria J Merino; Dragana Milosevic; Jiří Widimský; Karel Pacak
Journal:  Eur J Clin Invest       Date:  2011-04-01       Impact factor: 4.686

Review 7.  Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.

Authors:  Oksana Hamidi; William F Young; Lucinda Gruber; John Smestad; Qi Yan; Oscar J Ponce; Larry Prokop; Mohammad Hassan Murad; Irina Bancos
Journal:  Clin Endocrinol (Oxf)       Date:  2017-08-17       Impact factor: 3.478

8.  Giant malignant cystic pheochromocytoma: a case report.

Authors:  Mehdi Soufi; Mohammed K Lahlou; Said Benamr; Rahal Massrouri; Jalil Mdaghri; Abdelhamid Essadel; Mohammadine El Hamid; Ahmed Taghy; Abdelatif Settaf; Bouziane Chad
Journal:  Indian J Surg       Date:  2012-08-12       Impact factor: 0.656

Review 9.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.

Authors:  Hui Huang; Jame Abraham; Elizabeth Hung; Steven Averbuch; Maria Merino; Seth M Steinberg; Karel Pacak; Tito Fojo
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.